Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.64 |
| ▸ | CTSK | P43235 | 7/20 | 0.64 |
| ▸ | CTSB | P07858 | 2/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | MMP14 | P50281 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764798 | 1.00 | CTSS (0.64) | CTSSCTSKCTSBCTSLMMP9 | |
| SCHEMBL3701014 | 0.94 | CTSS (0.66) | CTSSCTSKCTSBCTSLMMP9 | |
| SCHEMBL3701013 | 0.94 | CTSS (0.66) | CTSSCTSKCTSBCTSLMMP9 | |
| SCHEMBL4654379 | 0.90 | CTSS (0.61) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL4654386 | 0.90 | CTSS (0.61) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1204211 | 0.88 | JAK3 (0.61) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL8894210 | 0.88 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL18057248 | 0.88 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL19969174 | 0.88 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6557659 | 0.88 | JAK3 (0.61) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |